Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Jane Street Group LLC lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 52,998 shares of the specialty pharmaceutical company’s stock after selling 848 shares during the period. Jane Street Group LLC owned about 0.10% of Supernus Pharmaceuticals worth $1,652,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SUPN. Louisiana State Employees Retirement System boosted its stake in shares of Supernus Pharmaceuticals by 2.2% during the 2nd quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock worth $741,000 after acquiring an additional 600 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Supernus Pharmaceuticals by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 425,387 shares of the specialty pharmaceutical company’s stock worth $11,379,000 after purchasing an additional 2,427 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Supernus Pharmaceuticals by 20.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,083 shares of the specialty pharmaceutical company’s stock worth $350,000 after purchasing an additional 2,225 shares during the last quarter. Innealta Capital LLC purchased a new stake in Supernus Pharmaceuticals during the second quarter worth $51,000. Finally, Commonwealth Equity Services LLC grew its holdings in Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock valued at $273,000 after purchasing an additional 350 shares during the last quarter.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Georges Gemayel sold 14,213 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now directly owns 13,315 shares in the company, valued at approximately $487,595.30. This represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Up 1.9 %

NASDAQ SUPN opened at $36.28 on Friday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37. The business has a fifty day moving average of $35.83 and a 200-day moving average of $32.45. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of 33.91 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.29) EPS. As a group, analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.